Context Therapeutics Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2026-06-30; filed 2026-08-05.
0001628280-26-053347
Item 1A. Risk FactorsCurrent report: 10-Q
Period ended 2026-09-30; filed 2026-11-10.
0001628280-26-072730
Item 1A. Risk FactorsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 7 previous paragraphs and 14 current paragraphs.
5 unchanged; 1 reworded; 8 added; 0 removed; 1 previous and 0 current paragraphs rearranged.
Tables are not compared: 0 previous and 0 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (8)
Current report
There is substantial doubt regarding our ability to continue as a going concern. We will require additional capital to fund our operations, and if we are unable to obtain sufficient capital, we may need to curtail and reduce our operations and costs and modify our business strategy.
Current report
Our operations have consumed substantial amounts of cash. We have funded our operations primarily through the sale of common stock, warrants, convertible debt, and convertible preferred stock. The continuation of our business is dependent upon raising additional capital. We will need additional funding to meet our operational needs and capital requirements for clinical trials, other research and development expenditures, and general and administrative expenses. We currently have no credit facility or committed sources of capital. We believe our cash and cash equivalents of $34.4 million as of September 30, 2026 are not sufficient to fund our projected operations for a period of at least 12 months from the issuance date of the accompanying unaudited condensed consolidated financial statements. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.
Current report
If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may need to curtail and reduce our operations and costs and modify our business strategy, which may require us to, among other things:
Current report
•significantly delay, scale back or discontinue the development of one or more of our product candidates;
Current report
•sell or license, on unfavorable terms, our rights to one or more of our technologies or product candidates that we otherwise would seek to develop or commercialize ourselves;
Current report
•seek to sell our company at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or
Current report
•cease operations, liquidate some or all of our assets or pursue a wind-down and dissolution of our company.
Current report
If we cease operations or pursue a liquidation, wind-down or dissolution, our stockholders could lose all or a substantial portion of their investment.
Reworded paragraphs (1)
Previous wording
(the “Minimum Bid Price Requirement”). Nasdaq’s notice has no immediate effect on the listing of our common stock, and, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have until January 25, 2027 to regain compliance with the Minimum Bid Price Requirement by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days, unless Nasdaq exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). In the event that we do not regain compliance by January 25, 2027, we may be eligible for additional time to regain compliance with the Minimum Bid Price Requirement.
Current wording
For example, on July 29, 2026, we received a letter from Nasdaq notifying us that, because the closing bid price for our common stock had closed below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Nasdaq’s notice has no immediate effect on the listing of our common stock, and, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have until January 25, 2027 to regain compliance with the Minimum Bid Price Requirement by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days, unless Nasdaq exercises its discretion to extend this ten-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). In the event that we do not regain compliance by January 25, 2027, we may be eligible for additional time to regain compliance with the Minimum Bid Price Requirement. However, under Nasdaq’s listing rules, if the closing bid price of our common stock is $0.10 per share or less for ten consecutive business days, we would not be eligible for a compliance period, Nasdaq would issue a delisting determination and suspend trading of our common stock on Nasdaq, and an appeal of such determination would not stay the suspension.
Rearranged previous paragraphs (1)
Previous report — wording carried elsewhere
For example, on July 29, 2026, we received a letter from Nasdaq notifying us that, because the closing bid price for our common stock had closed below $1.00 per share for 30 consecutive business days, we no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2)